From Entresto To Ozempic: This Week In Generics Litigation
Friction between brand-name and generic-drug makers escalated this past week, with the D.C. Circuit rejecting Novartis' challenge to a generic for heart medication Entresto, Pfizer looking to enforce a patent over its anti-inflammatory drug...To view the full article, register now.
Already a subscriber? Click here to view full article